Guangzhou, China– August , 2024 – Inc. “The EC approval of BAT2206 is anothersignificant accomplishment for Bio-Thera as it marks Bio-Thera’s third EC approvedproduct” said Shengfeng Li, CEO at Bio-Thera. “Bio-Thera is committed toexpanding access fo...
View Details· CHMP positive opinion is based on a robust analytical,non-clinical and clinical data package comparing to the reference product Stelara® Guangzhou,China– June , 2024 –Bio-TheraSolutions Inc.USYMRO® USYMRO®. “Bio-Therais committed to being one of th...
Download Poster_Safety and efficacy of BAT8006, a folate receptor α (FRα) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: Update on the dose optimization/expansion cohort of BAT-8006-001-CR trial.Download Poster_BAT8008, ...
Guangzhou and London – May 22, 2025) Injection, a biosimilarreferencing Stelara® (ustekinumab) Injection. STARJEMZA® is Bio-Thera’s third FDA approved product. “The approval of STARJEMZA® is another significantaccomplishment for Bio-Thera, establishi...
